Journal profile · Toxicology
Regulatory Toxicology and Pharmacology
ISSN 0273-2300 · eISSN 1096-0295 · Academic Press Inc. · UNITED STATES · Monthly · Founded 1981
Regulatory Toxicology and Pharmacology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.24; hybrid open access; APC about USD 4,210; median 125 days to acceptance (119 articles, last 24 months); community-reported acceptance: about 25%; 187 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Regulatory Toxicology and Pharmacology is published by Academic Press Inc. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Carcinogens and Genotoxicity Assessment, Effects and risks of endocrine disrupting chemicals and Animal testing and alternatives, together about 34.8% of its articles. Its main subfields are Health, Toxicology and Mutagenesis. (generated from OpenAlex topic counts and CAS ranking data)
Regulatory Toxicology and Pharmacology publishes peer reviewed articles that involve the generation, evaluation, and interpretation of experimental animal and human data that are of direct importance and relevance for regulatory authorities with respect to toxicological and pharmacological regulations in society. All peer-reviewed articles that are published should be devoted to improve the protection of human health and environment. Reviews and discussions are welcomed that address legal and/or regulatory decisions with respect to risk assessment and management of toxicological and pharmacological compounds on a scientific basis. It addresses an international readership of scientists, risk assessors and managers, and other professionals active in the field of human and environmental health.Types of peer-reviewed articles published:Original research articles of relevance for regulatory aspects covering aspects including, but not limited to:Factors influencing human sensitivityExposure science related to risk assessmentAlternative toxicological test methodsFrameworks for evaluation and integration of data in regulatory evaluationsHarmonization across regulatory agenciesRead-across methods and evaluationsContemporary Reviews on policy related Research issuesLetters to the EditorGuest Editorials (by Invitation)News on recent or upcoming policy related Research issues, outcomes of regulatory expert meetings with implications for risk assessment and managementRTP Tobacco policyRegulatory Toxicology and Pharmacology, as the journal serving developments for improvement of human health and environment, will not consider manuscripts that have been supported by tobacco companies.
From the journal's Aims & Scope
Research area (LetPub): Toxicology
Editor-in-chief Martin van den BergPublisher website
Editorial board by country: 5 in mainland China (about 10%); most named United States 17, Netherlands 8, Mainland China 5, United Kingdom 3, Japan 2 (48 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Carcinogens and Genotoxicity AssessmentBiochemistry, Genetics and Molecular Biology14.1%
- Effects and risks of endocrine disrupting chemicalsEnvironmental Science12.7%
- Animal testing and alternativesVeterinary8%
- Pesticide Exposure and ToxicityAgricultural and Biological Sciences5.6%
- Toxic Organic Pollutants ImpactEnvironmental Science5.3%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.6%
- Air Quality and Health ImpactsEnvironmental Science4.4%
- Contact Dermatitis and AllergiesMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medicine, Legal | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Toxicology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medicine, Legal | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Toxicology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Legal | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Toxicology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.24LetPub ·
- Impact factor (publisher)
- 4.3Publisher website ·
- CiteScore 2026-06
- 7.2LetPub ·
- CiteScore (publisher)
- 7.2Publisher website ·
- SJR 2026-06
- 1.12LetPub ·
- SNIP 2026-06
- 1.31LetPub ·
- h-index
- 90LetPub ·
- h-index
- 155OpenAlex ·
- i10-index
- 3,390OpenAlex ·
- 2-year mean citedness
- 3.73OpenAlex ·
- Self-citation rate
- 11.6%LetPub ·
- Share of gold OA articles
- 39.05%LetPub ·
Volume
- Articles per year
- 164LetPub ·
Articles by year OpenAlex count · 6,023 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 181 | 75 | 76 |
| 2025 | 187 | 86 | 582 |
| 2024 | 156 | 82 | 1,295 |
| 2023 | 169 | 99 | 2,047 |
| 2022 | 158 | 86 | 2,489 |
| 2021 | 190 | 91 | 3,870 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
125 daysMedian, submission to acceptance · P25–P75 81 days – 162 days
- Acceptance to online
- median 2 days (119 articles)
- Submission to online
- median 131 days
- Sample
- 119 articles with submission and acceptance dates (410 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- 25%LetPub ·
- Submission to first decision
- 12 daysPublisher website ·
- First decision after review
- 57 daysPublisher website ·
- Submission to acceptance
- 101 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,210 / EUR 3,940 / GBP 3,370 / JPY 522,170 | — | — | |
| Publisher website | USD 4,250 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Abstract
- ≤ 200 words
- Keywords
- 1–7
- Manuscript length
- ≤ 2,500 words
Article types accepted11, with length limits
- commentariesCommentaries are published that focus on a specific topic relating to regulatory aspects or legislation but are written on a strictly scientific basis.Length not stated
- commentaryc topic is appropriate for the journal. Commentaries should contain no more than 2500 words and 50 references and 2 figures and/or tables. The Editorsmain text ≤ 2,500 words · figures and tables ≤ 2 · references ≤ 50
- comprehensive reviewsComprehensive Reviews are extensive reviews on important topics for the regulatory and policy arena.Length not stated
- contemporary reviewsContemporary Reviews focus on policy-related research issues and should provide an overview or highlights of recent research on a scientific topic that is of di…Length not stated
- editorialthe discussion on a given topic. Guest Editorials Guest Editorials are by invitation only and should not be longer than 1000 words and 5 references. The content…main text ≤ 1,000 words
- guest editorialsGuest Editorials are by invitation only and should not be longer than 1000 words and 5 references.Length not stated
- letteron, based on scientific evidence. These Letters to the Editors should not exceed 1000 words and 5 references. If needed one table or figure can be addemain text ≤ 1,000 words · references ≤ 5
- letters to the editorsLetter to the Editors refer to an article published in the journal and includes omissions or reflects differences in opinion, based on scientific evidence.Length not stated
- original research articled to their regulatory application These Original Research Articles should contain no more than 5000 words, excluding references, and not more than a total of 5 …main text ≤ 5,000 words
- reviewciated legislations. These Contemporary Reviews should contain no more than 2500 words and 50 references and 2 figures and/or tables. Supplementarmain text ≤ 2,500 words
- workshop reportsWorkshop Reports should provide a concise overview of the context and purpose of the workshop, highlighting key themes and findings, as well as identification o…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints, Trial registration / reporting guidelines
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·- Trial registration / reporting guidelines
Will not consider manuscripts supported by tobacco companies Model summary
Regulatory Toxicology and Pharmacology, as the journal serving developments for improvement of human health and environment, will not consider manuscripts that have been supported by tobacco companies.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Academic Press Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1981
- ISSN
- 0273-2300
- Electronic ISSN
- 1096-0295
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Regulatory Toxicology and Pharmacology
What CAS zone is Regulatory Toxicology and Pharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Regulatory Toxicology and Pharmacology is in Zone 3 of Medicine, and in Zone 3 of the minor category Medicine, Legal / Pharmacology & Pharmacy / Toxicology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Regulatory Toxicology and Pharmacology?
The latest impact factor listed by LetPub is 4.24; CiteScore 7.2, h-index 155.
How long does peer review take at Regulatory Toxicology and Pharmacology?
Based on the dates recorded on 119 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 125 days (interquartile range 81–162 days); authors report an average review time of about 3 months; the community-reported acceptance is “about 25%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Regulatory Toxicology and Pharmacology?
According to the journal's author guidelines: Abstract: ≤ 200 words; Keywords: 1–7; Manuscript length: ≤ 2,500 words. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Regulatory Toxicology and Pharmacology based?
Of the 48 board members whose country the journal's board page names, 5 (about 10%) are in mainland China; the countries named most often are United States (17), Netherlands (8) and Mainland China (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Regulatory Toxicology and Pharmacology?
According to LetPub and DOAJ records, Regulatory Toxicology and Pharmacology is indexed in SCIE and Scopus.
Is Regulatory Toxicology and Pharmacology open access, and what is the APC?
Regulatory Toxicology and Pharmacology is a hybrid journal. For open-access publication: APC about USD 4,210.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .